Established in 1993, Atlantis Healthcare has offices in Australia, Germany, New Zealand, Spain, the United Kingdom and United States providing a unique service to address the issue of treatment non-adherence.
Atlantis Healthcare is dedicated to improving patient outcomes in a way that also delivers significant value to our clients, and healthcare systems. Our patient centred solutions tackle treatment non-adherence head-on to deliver better health outcomes for all and reduce wastages in medical spending.
Atlantis creates engaging adherence and self-management programmes for patients and clinicians. Each programme captures the adherence profile of an individual patient, their medication and illness beliefs and their specific support needs. This ensures interventions address the underlying drivers of non-adherence on an individual patient basis to drive long-term behaviour change.
“However effective a drug has been proven to be, it won’t work unless a patient takes it properly.”
– Professor John Weinman, Head of Health Psychology – Europe, Atlantis Healthcare
Adherence solutions company Atlantis Healthcare founded its Spanish affiliate in 2010. Ana Maria Arboleda, managing director, discusses adherence issues in Spain and efforts to ensure that patients remain committed to…
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona.…
Aiming to leverage European Union funds to reindustrialise its economy, the Spanish government has approved a public-private collaboration instrument to transform its health sector. The project looks to position Spain…
The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain – including the nearly EUR one billion in…
The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and…
Walt Vernon is CEO of US-based healthcare facilities consulting firm, Mazzetti, and non-profit, Sextant. He is on the Board of the FGI and served on NFPA 99 ELS, NFPA 70…
The Lymphoma Coalition’s Natacha Bolaños outlines the fundamentals of the lymphoma patient experience today, the growing number of innovative new treatment options available, and the issues surrounding their integration as…
The Spanish pharma industry has entered the race to develop COVID-19 vaccines through an unexpected contender: an animal health company. HIPRA, headquartered in Catalonia, has received approval to begin human…
The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP protection for medical advancements, Grifols’ expansion in Africa through a manufacturing plant in…
The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an…
The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at…
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a…
See our Cookie Privacy Policy Here
